Sonoma Pharmaceuticals Inc (SNOA) Stock Analysis
Verdict: HOLD
First-ever positive EBITDA and record revenue signal a structural turnaround, but 1,700% share dilution since 2019 demands extreme caution.
Investment score: 62/100
Analysis as of
Is Sonoma Pharmaceuticals Inc stock worth reviewing? The TradeMates thesis
SNOA is transitioning from a perennial cash-burner to a potentially self-sustaining entity. While historical dilution is a massive red flag, the current valuation fails to account for the recent EBITDA pivot.
7-factor investment score
- Valuation: 85/100 (weight 20%)
- Financial Health: 55/100 (weight 15%)
- Technical Momentum: 70/100 (weight 15%)
- Earnings Quality: 75/100 (weight 15%)
- Insider Sentiment: 40/100 (weight 10%)
- Analyst Consensus: 50/100 (weight 10%)
- Risk-Adjusted Return: 45/100 (weight 15%)
Sonoma Pharmaceuticals Inc opportunities and risks
What speaks for SNOA
- Positive EBITDA Inflection
What speaks against SNOA
- Chronic Share Dilution History
Peers and competitors
- CNSP
- PCSA
- CVKD
- SNES
- PLSH
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| SNOA | n/a | 0.1x | 1.4x | 38.9% | -10.3% | -88.7% |
| CNSP | n/a | 0.0x | n/a | 0.0% | 0.0% | -193.9% |
| PCSA | n/a | 0.0x | n/a | 0.0% | 0.0% | -172.1% |
| CVKD | n/a | 0.0x | n/a | 0.0% | 0.0% | -181.3% |
| SNES | n/a | 2.9x | n/a | 64.9% | -294.7% | -98.5% |
| PLSH | n/a | 4.8x | n/a | -341.2% | -916.7% | -0.4% |
| Peer median | n/a | 0.0x | n/a | 0.0% | 0.0% | -172.1% |
Frequently asked questions about Sonoma Pharmaceuticals Inc (SNOA)
Is SNOA stock a good investment?
The TradeMates model rates Sonoma Pharmaceuticals Inc as HOLD with an investment score of 62/100. SNOA is transitioning from a perennial cash-burner to a potentially self-sustaining entity. While historical dilution is a massive red flag, the current valuation fails to account for the recent EBITDA pivot. This is algorithmic model output, not personal investment advice.
Is SNOA stock a buy?
The TradeMates model verdict for SNOA is HOLD with an investment score of 62/100. Treat this as a model signal to review, not a personal buy recommendation.